Remdesivir-associated bradycardia

Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ching, Patrick R, Lee, Calvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420729/
https://www.ncbi.nlm.nih.gov/pubmed/34479903
http://dx.doi.org/10.1136/bcr-2021-245289
_version_ 1783748937269641216
author Ching, Patrick R
Lee, Calvin
author_facet Ching, Patrick R
Lee, Calvin
author_sort Ching, Patrick R
collection PubMed
description Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using β-blockers.
format Online
Article
Text
id pubmed-8420729
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84207292021-09-22 Remdesivir-associated bradycardia Ching, Patrick R Lee, Calvin BMJ Case Rep Case Report Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using β-blockers. BMJ Publishing Group 2021-09-03 /pmc/articles/PMC8420729/ /pubmed/34479903 http://dx.doi.org/10.1136/bcr-2021-245289 Text en © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Case Report
Ching, Patrick R
Lee, Calvin
Remdesivir-associated bradycardia
title Remdesivir-associated bradycardia
title_full Remdesivir-associated bradycardia
title_fullStr Remdesivir-associated bradycardia
title_full_unstemmed Remdesivir-associated bradycardia
title_short Remdesivir-associated bradycardia
title_sort remdesivir-associated bradycardia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420729/
https://www.ncbi.nlm.nih.gov/pubmed/34479903
http://dx.doi.org/10.1136/bcr-2021-245289
work_keys_str_mv AT chingpatrickr remdesivirassociatedbradycardia
AT leecalvin remdesivirassociatedbradycardia

Ejemplares similares